NMRA-335140 80 mg
DrugParticipants will receive NMRA-335140 at a dose of 80 mg QD, orally.
Other names: BTRX-335140, CYM-53093, Navacaprant
NCT Number: NCT06429722
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Neumora Investigator Site, Phoenix, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
Other names: BTRX-335140, CYM-53093, Navacaprant
Placebo will be administered orally
Time frame: Baseline and up to Week 6
The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7- point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. Thus, scores in the MADRS range from 0 to 60, with increasing scores indicating increasing severity.
Time frame: Baseline and up to Week 6
The SHAPS is a 14-item participant-reported instrument which measures anhedonia. It has been shown to be valid and reliable in normal and clinical samples, with adequate construct validity, satisfactory test-retest reliability, and high internal consistency. The scale will be completed by the participant and reviewed by site personnel qualified to oversee completeness. Each of the 14 items has a set of 4 responses, 2 of which endorse agreement (Definitely Agree, Agree) and 2 of which endorse disagreement (Disagree, Strongly Disagree). A total score can be derived by summing the response items; where those answered with "strongly agree" will be coded as a 1, while a "strongly disagree" response will be coded as 4. Therefore, scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
Neumora Therapeutics, Inc.
Industry
A Phase 2a, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With a Major Depressive Episode Associated With Bipolar II Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07404943
Behavior, Bi-Polar Disorder
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT06365021
Bipolar Disorder, Bipolar and Related Disorders
São Paulo, Brazil
View Trial DetailsNCT06462586
Bipolar Disorder, Bipolar Disorder, Manic
Rogers, Arkansas, United States
View Trial DetailsNCT06462612
Bipolar Disorder, Bipolar Disorder, Manic
Bentonville, Arkansas, United States
View Trial Details